Artificial Intelligence

DeepCyte Raises US$1.5M to Use AI and Single-Cell Analysis to Predict Drug Toxicity

A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.

Updated

April 15, 2026 6:01 PM

Close up of a capsule blister pack. PHOTO: UNSPLASH

DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.

The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.

Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.

DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.

Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.

The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.

Keep Reading

Artificial Intelligence

X-Humanoid Introduces Tien Kung 3.0 as Deployment Challenges Persist in Humanoid Robotics

A closer look at the tech, AI, and open ecosystem behind Tien Kung 3.0’s real-world push

Updated

March 17, 2026 1:02 AM

Humanoid robots working in a warehouse. PHOTO: ADOBE STOCK

Humanoid robotics has advanced quickly in recent years. Machines can now walk, balance, and interact with their surroundings in ways that once seemed out of reach. Yet most deployments remain limited. Many robots perform well in controlled settings but struggle in real-world environments. Integration is often complex, hardware interfaces are closed, software tools are fragmented, and scaling across industries remains difficult.

Against this backdrop, X-Humanoid has introduced its latest general-purpose platform, Embodied Tien Kung 3.0. The company positions it not simply as another humanoid robot, but as a system designed to address the practical barriers that have slowed adoption, with a focus on openness and usability.

At the hardware level, Embodied Tien Kung 3.0 is built for mobility, strength, and stability. It is equipped with high-torque integrated joints that provide strong limb force for high-load applications. The company says it is the first full-size humanoid robot to achieve whole-body, high-dynamic motion control integrated with tactile interaction. In practice, this means the robot is designed to maintain balance and execute dynamic movements even in uneven or cluttered environments. It can clear one-meter obstacles, perform consecutive high-dynamic maneuvers, and carry out actions such as kneeling, bending, and turning with coordinated whole-body control.

Precision is also a focus. Through multi-degree-of-freedom limb coordination and calibrated joint linkage, the system is designed to achieve millimeter-level operational accuracy. This level of control is intended to support industrial-grade tasks that require consistent performance and minimal error across changing conditions.

But hardware is only part of the equation. The company pairs the robot with its proprietary Wise KaiWu general-purpose embodied AI platform. This system supports perception, reasoning, and real-time control through what the company describes as a coordinated “brain–cerebellum” architecture. It establishes a continuous perception–decision–execution loop, allowing the robot to operate with greater autonomy and reduced reliance on remote control.

For higher-level cognition, Wise KaiWu incorporates components such as a world model and vision-language models (VLM) to interpret visual scenes, understand language instructions, and break complex objectives into structured steps. For real-time execution, a vision-language-action (VLA) model and full autonomous navigation system manage obstacle avoidance and precise motion under variable conditions. The platform also supports multi-agent collaboration, enabling cross-platform compatibility, asynchronous task coordination, and centralized scheduling across multiple robots.

A central part of the platform is openness. The company states that the system is designed to address compatibility and adaptation challenges across both development and deployment layers. On the hardware side, Embodied Tien Kung 3.0 includes multiple expansion interfaces that support different end-effectors and tools, allowing faster adaptation to industrial manufacturing, specialized operations, and commercial service scenarios. On the software side, the Wise KaiWu ecosystem provides documentation, toolchains, and a low-code development environment. It supports widely adopted communication standards, including ROS2, MQTT, and TCP/IP, enabling partners to customize applications without rebuilding core systems.

The company also highlights its open-source approach. X-Humanoid has open-sourced key components from the Embodied Tien Kung and Wise KaiWu platforms, including the robot body architecture, motion control framework, world model, embodied VLM and cross-ontology VLA models, training toolchains, the RoboMIND dataset, and the ArtVIP simulation asset library. By opening access to these elements, the company aims to reduce development costs, lower technical barriers, and encourage broader participation from researchers, universities, and enterprises.

Embodied Tien Kung 3.0 enters a market where technical progress is visible but large-scale adoption remains uneven. The gap is not only about movement or strength. It is about integration, interoperability, and the ability to operate reliably and autonomously in everyday industrial and commercial settings. If platforms can reduce fragmentation and simplify deployment, humanoid robots may move beyond demonstrations and into sustained commercial use.

In that sense, the significance of Embodied Tien Kung 3.0 lies less in isolated technical claims and more in how its high-dynamic hardware, embodied AI system, open interfaces, and collaborative architecture are structured to work together. Whether that integrated approach can close the deployment gap will shape how quickly humanoid robotics becomes part of real-world operations.